Therapeutic Advances and AE Management in NF1-Associated Plexiform Neurofibromas

Timothy R. Gershon, MD, PhD, discusses ongoing research priorities neurofibromatosis type 1–associated plexiform neurofibromas

Timothy Gershon, MD, PhD, discusses how the FDA approval of mirdametinib will affect the treatment paradigm for adult patients with NF1-associated PNs.

Justin T. Jordan, MD, MPH, FAAN, discusses the implications of the FDA approval of mirdametinib for adult NF1-associated plexiform neurofibromas.

Justin T. Jordan, MD, MPH, FAAN, discusses treatment challenges and recent progress made with targeted therapies in adult NF1-associated PNs.

Dr Moertel discusses the expansion of the NF1-associated PN treatment paradigm to include the MEK inhibitors mirdametinib and selumetinib.

Rene Y. McNall-Knapp, MD, discusses the current treatment paradigm for pediatric and adult patients with NF1-associated PNs.

Rene Y. McNall-Knapp, MD, discusses the symptom management associated with mirdametinib and MEK inhibition in NF1-associated PNs.

Christopher L. Moertel, MD, discusses the management of MEK inhibitor–associated toxicities in NF1-associated plexiform neurofibromas.

Christopher L. Moertel, MD, discusses advances and ongoing research in NF1-associated plexiform neurofibromas.